Clinical Immunogenicity of DaxibotulinumtoxinA for Injection in Glabellar Lines: Pooled Data from the SAKURA Phase 3 Trials
Sign Up to like & getrecommendations! Published in 2023 at "Toxins"
DOI: 10.3390/toxins15010060
Abstract: DaxibotulinumtoxinA for Injection (DAXI) is a novel botulinum toxin type A product containing daxibotulinumtoxinA with a stabilizing excipient peptide (RTP004). DAXI immunogenicity was assessed in three phase 3 glabellar line studies (two placebo-controlled, single-dose studies… read more here.
Keywords: daxi; binding antibodies; daxibotulinumtoxina; daxibotulinumtoxina rtp004 ... See more keywords